Pai.ACT Programme for Parents of Children With Special Healthcare Needs - Phase I
Launched by CHINESE UNIVERSITY OF HONG KONG · Oct 14, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Pai.ACT Programme is a clinical trial designed to help parents of children with special healthcare needs, such as neurodevelopmental disorders, ADHD, autism, and other chronic conditions. This study will explore how effective and acceptable video-based therapy sessions, known as Focused Acceptance and Commitment Therapy (FACT), are for improving the mental well-being of these parents. The goal is to see how parents feel after participating in these individual therapy sessions with trained professionals.
To join this trial, parents must be Cantonese-speaking residents of Hong Kong, living with a child aged 3 to 9 years who has special healthcare needs. Participants should also have daily access to a smartphone. The study is currently recruiting and is open to all genders. It's important to note that parents with severe mental health issues that could affect their ability to engage in the program will not be eligible. Participants can expect to share their experiences and learn strategies to cope better with the challenges of caring for their children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cantonese-speaking Hong Kong residents
- • living together with the child who is at preschool/school-age (3-9 years old)
- • adopt the responsibility of taking care of the child,
- • has daily access to their iPhone and Android smartphones.
- • In addition, potential eligible parents who respond "yes" to any of the five validated screening questions in the Children with Special Health Care Needs (SHCN) Screener (see https://www.childhealthdata.org/docs/cshcn/technical-summary-of-cshcn-screener.pdf) will then be asked the associated follow-up questions to determine whether the child possesses physical, neurodevelopmental/emotional problem(s) that has lasted for at least 12 months. Only children with a positive response(s) to ≥ 1 item in each of the associated follow-up questions will be classified as children with SHCN.
- Exclusion Criteria:
- • Parents with severe mental illness or developmental disabilities which impaired their ability to comprehend the content of the programme will be excluded.
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Yuen Yu Chong, PhD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials